Hansa Medical postpones annual general meeting

Hansa Medical AB (publ) has decided to postpone its annual general meeting, AGM, until June 2, 2015.

The AGM will be held in Lund at 17.00 CET. It has previously been planned for April 16, 2015. A complete notice to the AGM will be released no later than May 5, 2015.

The reason for the postponing of the AGM is the recent change of ownership in Hansa Medical and the large rights issue currently under way.

The information in this press release was released for public disclosure on March 16, 2015 at 08.00.

For further information, please contact:
Hansa Medical AB
Göran Arvidson, CFO and acting CEO
Mobile: +46 706-33 30 42
E-mail: goran.arvidson@hansamedical.com



About Us

Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market introduced diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's share (HMED) is listed on Nasdaq First North in Stockholm with Remium Nordic AB as Certified Adviser.